Remove Clinical Trials Remove Drugs Remove In-Vitro Remove In-Vivo
article thumbnail

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Drug Discovery World

Grown in vitro, these cells can provide patient specific human brain models from a large cohort of AD patients – to create a ‘clinical trial in a dish’. The recent US Federal Food and Drug Administration Agency (FDA) Modernization Act 2.0

article thumbnail

How Much Do You Know About in silico Trials?

XTalks

Conventional in vitro and in vivo studies are used in the drug development pipeline. This involves the use of an individualized computer simulation for medical device or drug development. Take this quiz to test your knowledge about in silico trials! Want to learn more?

Trials 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investigating potential for an oral treatment in diabetic retinopathy  

Drug Discovery World

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).

article thumbnail

Only non-US company joins cancer drug discovery consortium

Drug Discovery World

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The post Only non-US company joins cancer drug discovery consortium appeared first on Drug Discovery World (DDW).

Drugs 52
article thumbnail

Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety

pharmaphorum

German drugmaker Merck KGaA has reached an agreement to pilot an artificial intelligence platform developed by Quris that aims to identify potential safety problems with new therapeutic candidates as early as possible in the drug discovery process.

Drugs 98
article thumbnail

Closing the translation gap in oncology drug development

Drug Discovery World

Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval.

article thumbnail

News from AACR 2024: Sunday’s highlights

Drug Discovery World

Jakob Nikolas Kather, Professor of clinical artificial intelligence at Technical University Dresden in Germany, then discussed how AI applications can be used to derive prognostic and predictive information from routine pathology slides.

In-Vivo 52